

***In the Claims:***

Kindly amend claim 33, cancel claim 47, and insert new claims 53-54 as shown in the following listing of the entire claims in the application.

1 – 11 (canceled)

12 – 23. (canceled)

24. (withdrawn) A method of preparing a derivative from a naturally occurring allergen, wherein specific IgE binding to the derivative is 50% or less compared to the IgE binding to said naturally occurring allergen, which method comprises:

modifying said naturally occurring allergen to induce IgG antibody production  
wherein the production of allergen-specific IgE is reduced.

25. (withdrawn) The method of claim 24, wherein the IgE binding to the derivative is 25% or less compared to the IgE binding to said naturally occurring allergen.

26. (withdrawn) The method of claim 24, wherein the IgE binding to the derivative is 10% or less compared to the IgE binding to said naturally occurring allergen.

27. (withdrawn) The method of claim 24, wherein the IgE binding to the derivative is 5% or less compared to the IgE binding to said naturally occurring allergen.

28. (withdrawn) The method of claim 24, wherein the IgE binding to the derivative is eliminated compared to the IgE binding to said naturally occurring allergen.

29. (withdrawn) The method of claim 24, wherein the specific IgG isotype induced is IgG<sub>1</sub> and IgG<sub>2</sub>.

30. (withdrawn) The method of claim 24, wherein, the specific IgG isotype induced is IgG<sub>1</sub>, IgG<sub>2</sub> and IgG<sub>4</sub>.

31. (withdrawn) The method of claim 24, wherein the naturally occurring allergen is Bet v 1.

32. (withdrawn) The method of claim 24, wherein the naturally occurring allergen is selected from the group consisting of major grass pollen allergens, mite allergens, bee venom allergens and animal hair dander allergens.

33. (currently amended) A method of treating or preventing a human IgE-mediated allergic disorder, comprising periodically administering for a number of times to a patient in need

thereof, a composition comprising one or more immunotherapeutic agents selected by a process involving:

providing derivatives from naturally occurring ~~grass-pollen~~ allergens selected from the group consisting of the major allergens of alder, hazel and birch;

challenging an immunological model with said derivatives;

selecting as immunotherapeutic agents, those derivatives which induce IgE-blocking antibodies and wherein specific IgE binding to the derivative is 50% or less compared to IgE binding to said naturally occurring allergen.

34. (previously presented) The method of claim 33, wherein the IgE binding to the derivative is 25% or less compared to the IgE binding to said naturally occurring allergen.

35. (canceled)

36. (canceled)

37. (previously presented) The method of claim 33, wherein the derivative elicits substantially no allergenic activity compared to the IgE binding to said naturally occurring allergen.

38. (previously presented) The method of claim 33, wherein the period between administrations of the composition is at least 14 days.

39. (previously presented) The method of claim 38, wherein the composition is administered to the patient from three to five times.

40. (previously presented). The method of claim 39, wherein the composition is administered to the patient four times.

41. (previously presented) The method of claim 38, wherein the time interval between the third and the fourth administration being longer than the time intervals between the first three administrations.

42. (canceled)

43. (previously presented) The method of claim 33, wherein, during each administration, substantially the same dose of the derivative is administered.
44. (previously presented) The method of claim 43, wherein, during each administration, a dose of at least 5  $\mu$ g of the derivative is administered.
45. (previously presented) The method of claim 43, wherein, during each administration, a dose of at least 10  $\mu$ g of the derivative is administered.
46. (previously presented) The method of claim 33, wherein the naturally occurring allergen is Bet v 1.
47. (canceled)
48. (previously presented) The method of claim 33, wherein the composition further comprises an adjuvant.
49. (previously presented) The method of claim 33, wherein the immunotherapeutic agents are adsorbed unto a pharmaceutically acceptable adsorbate.
50. (previously presented) The method of claim 49, wherein the adsorbate is aluminum hydroxide.
51. (previously presented) The method of claim 33, wherein the immunotherapeutic agent is a derivative of Bet v 1.
52. (previously presented) The method of claim 33, wherein the immunotherapeutic agent is a trimer of Bet v 1.
53. (new) The method of claim 33, wherein the immunotherapeutic agent is a polypeptide consisting of amino acids 1-73 of Bet v1.

54. (new) The method of claim 33, wherein the immunotherapeutic agent is a polypeptide consisting of amino acids 74-159 of Bet v1.